NEOGEN CORP (NEOG) Stock Fundamental Analysis
NASDAQ:NEOG • US6404911066
11.32 USD
+0.02 (+0.18%)
At close: Feb 26, 2026
11.32 USD
0 (0%)
After Hours: 2/26/2026, 4:58:29 PM
Overall NEOG gets a fundamental rating of 3 out of 10. We evaluated NEOG against 185 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year NEOG was profitable.
- NEOG had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
- NEOG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -17.94%, NEOG is in line with its industry, outperforming 54.59% of the companies in the same industry.
- The Return On Equity of NEOG (-28.64%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -28.64% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 45.98%, NEOG is doing worse than 61.08% of the companies in the same industry.
- NEOG's Gross Margin has been stable in the last couple of years.
- NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
- NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
- NEOG has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for NEOG is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.35, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
- NEOG has a Altman-Z score of 1.35. This is comparable to the rest of the industry: NEOG outperforms 54.59% of its industry peers.
- NEOG has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
- NEOG has a Debt to Equity ratio (0.38) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.35 |
ROIC/WACCN/A
WACC10.09%
2.3 Liquidity
- NEOG has a Current Ratio of 3.91. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
- NEOG has a Current ratio of 3.91. This is in the better half of the industry: NEOG outperforms 65.41% of its industry peers.
- A Quick Ratio of 2.80 indicates that NEOG has no problem at all paying its short term obligations.
- NEOG has a Quick ratio of 2.80. This is in the better half of the industry: NEOG outperforms 63.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
- NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.50%.
- NEOG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.20% yearly.
- The Revenue has decreased by -3.67% in the past year.
- NEOG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.43% yearly.
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
3.2 Future
- The Earnings Per Share is expected to grow by 7.29% on average over the next years.
- Based on estimates for the next years, NEOG will show a decrease in Revenue. The Revenue will decrease by -0.50% on average per year.
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 39.03, NEOG can be considered very expensive at the moment.
- 70.81% of the companies in the same industry are more expensive than NEOG, based on the Price/Earnings ratio.
- NEOG's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.21.
- The Price/Forward Earnings ratio is 33.38, which means the current valuation is very expensive for NEOG.
- Based on the Price/Forward Earnings ratio, NEOG is valued a bit cheaper than the industry average as 70.27% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.13, NEOG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.03 | ||
| Fwd PE | 33.38 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NEOG is valued a bit cheaper than the industry average as 68.65% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.17 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y9.52%
5. Dividend
5.1 Amount
- No dividends for NEOG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
11.32
+0.02 (+0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-08 2026-01-08/bmo
Earnings (Next)04-07 2026-04-07
Inst Owners111.94%
Inst Owner Change-16.57%
Ins Owners0.61%
Ins Owner Change24.72%
Market Cap2.46B
Revenue(TTM)880.32M
Net Income(TTM)-602.74M
Analysts78.18
Price Target11.22 (-0.88%)
Short Float %5.51%
Short Ratio3.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.17%
Min EPS beat(2)78.25%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)32.2%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)3
Avg EPS beat(8)11.3%
EPS beat(12)5
Avg EPS beat(12)119.18%
EPS beat(16)6
Avg EPS beat(16)37.27%
Revenue beat(2)2
Avg Revenue beat(2)3.22%
Min Revenue beat(2)0.46%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.24%
Revenue beat(16)4
Avg Revenue beat(16)-0.78%
PT rev (1m)0%
PT rev (3m)44.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.69%
EPS NY rev (1m)0%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)3.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.03 | ||
| Fwd PE | 33.38 | ||
| P/S | 2.8 | ||
| P/FCF | N/A | ||
| P/OCF | 37.2 | ||
| P/B | 1.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.17 |
EPS(TTM)0.29
EY2.56%
EPS(NY)0.34
Fwd EY3%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.3
OCFY2.69%
SpS4.05
BVpS9.67
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -28.64% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.98% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score4
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.98 | ||
| Cap/Depr | 71.99% | ||
| Cap/Sales | 9.62% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 74.97% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 1.35 |
F-Score4
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%
EBIT growth 1Y-193.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.34%
EBIT Next 3Y34.61%
EBIT Next 5Y20.01%
FCF growth 1Y-209.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.22%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
What is the valuation status of NEOGEN CORP (NEOG) stock?
ChartMill assigns a valuation rating of 2 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 2 / 10.
What is the financial health of NEOGEN CORP (NEOG) stock?
The financial health rating of NEOGEN CORP (NEOG) is 4 / 10.
What is the expected EPS growth for NEOGEN CORP (NEOG) stock?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -9.33% in the next year.